Summary Tumour growth rates were measured in 105 patients using in vivo incorporation of bromodeoxyuridine (BrdU) and investigated for any relationship to tumour factors or survival. The median labelling index (LI) was 8.7%, the duration of S-phase (Ts) was 14 h and the potential doubling time (Tpo) was 5.9 days. The labelling index in aneuploid tumours was significantly higher than that in diploid tumours. However the total labelling index (TLI) did not differ significantly between aneuploid and diploid tumours, and so it would seem likely that the difference in LI is due to the dilutional effect of benign tissue upon the calculation of LI in diploid tumours. The total labelling index, duration of S-phase and potential doubling time were not related to the tumour factors examined (site, T The general approach to measuring cell kinetics is to identify a 'window' in the cell cycle and measure the movement of a particular cohort of cells through this window. BrdU, an analogue of thymidine, is incorporated into cells during the S-phase of the cell cycle. BrdU is non-toxic and non-radioactive and can be given intravenously to human patients. Infusions of BrdU at higher dosage can be tolerated for several weeks without severe myelosuppression (Mitchell et al., 1983; Kinsella et al., 1984) and there have been no reports of toxic reactions in any patients receiving BrdU at 200 mg m2. It is taken up by the tumour, and the proportion of cells that have taken up BrdU can be detected using monoclonal antibodies. Furthermore, a pulse label of BrdU can be given approximately 6 h before biopsy or excision of the tumour, allowing the length of S-phase to be calculated (Begg et al., 1985) . The simultaneous measurement of BrdU and DNA content using flow cytometry enables several cell kinetic parameters to be quantified. We have previously reported upon the cell kinetic results in 82 tumours and demonstrated their reproducibility (Forster et al., 1992) .
Patients with head and neck cancer have varying clinical courses, different responses to treatment and, as many patients present with advanced disease, a relatively poor prognosis. It has been suggested that measurement of cell kinetics in human tumours might provide prognostic information and allow prediction of response to radiotherapy or chemotherapy. We have evaluated this in part using the incorporation of bromodeoxyuridine into DNA as a marker of cell proliferation.
The general approach to measuring cell kinetics is to identify a 'window' in the cell cycle and measure the movement of a particular cohort of cells through this window. BrdU, an analogue of thymidine, is incorporated into cells during the S-phase of the cell cycle. BrdU is non-toxic and non-radioactive and can be given intravenously to human patients. Infusions of BrdU at higher dosage can be tolerated for several weeks without severe myelosuppression (Mitchell et al., 1983; Kinsella et al., 1984) and there have been no reports of toxic reactions in any patients receiving BrdU at 200 mg m2. It is taken up by the tumour, and the proportion of cells that have taken up BrdU can be detected using monoclonal antibodies. Furthermore, a pulse label of BrdU can be given approximately 6 h before biopsy or excision of the tumour, allowing the length of S-phase to be calculated (Begg et al., 1985) . The simultaneous measurement of BrdU and DNA content using flow cytometry enables several cell kinetic parameters to be quantified. We have previously reported upon the cell kinetic results in 82 tumours and demonstrated their reproducibility (Forster et al., 1992) .
In this study we present further cell kinetic data on 105 patients with squamous cell tumours of the head and neck and investigate the relationship to tumour stage, site and prognosis.
Method
Patients studied Ninety patients were treated in the Royal Liverpool Hospital and 15 patients in hospitals in Glasgow between August 1988 and April 1992. The tumours were staged using the UICC (1984) method and performance status assessed using the ECOG method (AJC, 1972) . Patient characteristics are shown in Table I . The median potential follow-up time was 11 months. These patients are part of an ongoing prospective study and the survival data on these patients should be viewed as an interim report. The majority of patients studied were undergoing major ablative surgery with curative intent. Forty-one patients had recurrent disease and had received previous treatment, largely with radiotherapy (DXT).
BrdU dosage and administration A single dose of 200 mg of freeze-dried BrdU in 20 ml of 0.9% saline was administered as an intravenous bolus. Three to 16 h later a biopsy or surgical excision was performed and the sample fixed in 70% ethanol and stored at 4°C until processing.
Flow cytometry
The flow cytometry methods of preparation and analysis have been described in detail previously (Forster et al., 1992) . In brief, tumour samples were minced as finely as possible with a scalpel and disaggregated into nuclei using 0.5% pepsin pH 1.5 at 37C for 30 min. The DNA was denatured with 2 M hydrochloric acid for 30 min at room temperature. The nuclear suspension was then incubated with mouse antiBrdU (Dako, High Wycombe, UK) at a dilution of 1:30 for 1 h at room temperature, washed and incubated with goat anti-mouse IgG fluorescein isothiocyanate-conjugated antibody (Sigma Chemical, Poole, UK) for 30 min at room temperature at a dilution of 1:40. Total DNA was stained using 10 ig ml-' propidium iodide and the samples analysed using a Coulter Epics Profile II flow cytometer.
The data derived from the flow cytometric profiles were the DNA ploidy, labelling index (LI) and the total labelling index (TLI). The Ts was derived using the method of Begg et al. (1985) and the Tpot using the formula: Tpot = A x Ts/LI where A was assumed to be 0.8 (Steel, 1977) . The method by which a labelling index can be measured in diploid tumours is slightly different from that in aneuploid tumours. In the latter case the LI of tumour nuclei alone can usually be obtained, whereas in diploid tumours the tumour nuclei are mixed with an unknown quantity of nuclei from normal tissue. An alternative method of comparing the LI in diploid and aneuploid tumours is to use the TLI, which measures the number of labelled nuclei in the whole sample, and hence the dilutional effect from normal nuclei occurs in both tumour types.
Tumour factors and cell kinetic measurements In order to determine whether there was any association between tumour factors (site, stage grouping, tumour size and nodal status) and cell kinetic parameters (TLI, Ts, Tpo) each was examined in turn. The TLI was used in preference to the LI as this was later shown to be associated with ploidy status. Cell kinetic measurements were compared between the four largest site groups.
Statistics
The results were analysed using a range of non-parametric techniques. Rates and proportions were analysed using the chi-squared test with Yates' correction where appropriate, and associations between continuous and ordered variables were assessed using the Spearman rank correlation coefficient. Survival curves were derived using Kaplan-Meier estimates, and groups compared using the log-rank test (Peto et al., 1977) . Continuous variables were analysed using the Mann-Whitney test when two groups were being compared, or the Kruskal-Wallis test when more than two groups were being compared. The results of these last two tests are reported in terms of H, the appropriate x2 statistic. The growth fraction of a tumour has been estimated using a variety of methods over the years. The use of tritiated thymidine was one of the first. In a series of 52 oral cavity carcinomas the mean thymidine labelling index was 11%, ranging from 0.01% to 50% (Silvestrini et al., 1984) . Greenberg et al. (1988) studied seven patients with a squamous carcinoma of the head and neck and found a median thymidine labelling index of 3.7%. They also noted considerable variability in multiple samples of the same tumour, ranging from 0.2 to 23.7%.
Flow cytometric estimation of the proportion of cells in S-phase has been performed by several groups. Ensley et al. (1989) reported that three-quarters of 165 patients with squamous carcinomas of the head and neck had an S-phase fraction (SPF) above 15% and that there was a strong direct correlation between DNA index and SPF. Franzen et al. (1986) found a mean SPF of 6.4% in diploid tumours, 10% in polyploid tumours and 19% in aneuploid tumours, with a range of 1-30% amongst 24 oral cavity carcinomas. Johnson et al. (1985) reported a mean SPF of 19% with a range of 4-45% in 45 patients with tumours at various sites within the head and neck.
Using in vitro labelling of cells with bromodeoxyuridine (Hemmer, 1990) , the values obtained for S-phase varied from 0 to 23.2% with a median of 2.6% among 33 primary previously untreated squamous cell carcinomas of the oral cavity. In contrast, Hirano et al. (1991) using a different method of in vitro bromodeoxyuridine labelling found a mean LI of 22.9% with a range of 9.15-33.5% among 24 squamous carcinomas from various sites within the head and neck region. The variation in LI reported between series probably reflects problems with reproducibility of both flow cytometric S-phase and in vitro BrdU methodologies, nevertheless the results of LI in this study fall within the range of previous observations.
Two centres have published cell kinetic studies in a large number of patients with a variety of malignancies using in vivo administration of bromodeoxyuridine and flow cytometry (Riccardi et al., 1988; Wilson, 1991) . Their results are similar to those in this series. Wilson found the duration of S-phase in head and neck tumours to be slightly shorter than our results (Table III) , whereas the figures in this study are closer to the values that they found in other types of tumour. In a study of 100 colorectal carcinomas the median values for LI, Ts and Tpo, were broadly similar to those found in squamous carcinoma of the head and neck (Rew et al., 1991) .
We observed no relationship between any of the cell kinetic parameters and tumour factors (site, stage grouping, T stage and nodal status), which is in agreement with most other studies (Hirano et al., 1991; Rew et al., 1991; Bennett et al., 1992) . However, in one reported series of 33 oral cavity carcinomas, the LIs of T3 tumours were significantly higher than those of TI and T2 carcinomas. There were also significantly higher LIs in primary tumours with lymph node metastases than in those without, but no difference as regards subsite or histological grading (Hemmer, 1990) . In a large series of 123 head and neck carcinomas there was no relationship between proliferation parameters and site, histological grading, T staging or nodal status (Bennett et al., 1992) .
In the present study there was no relationship between any of the cell kinetic parameters and an interim analysis of survival data. There have been very few publications examining tumour growth rates and prognosis in tumours of the head and neck region. Franzen et al. (1986) reported that the mean SPF was higher (16.1%) in a small group of eight oral cavity tumours eradicated by preoperative radiotherapy than for 13 that did not respond (8.1%). In contrast, pretreatment thymidine labelling index was not related to short-or longterm response to radiotherapy in another series of 52 oral cavity carcinomas, but a reduction of more than 70% in the thymidine labelling index after the first 10 Gy was associated with a good prognosis (Silvestrini et al., 1984) . In a preliminary evaluation of patients whose pretreatment cell kinetics was assessed using bromodeoxyuridine and who were in a pilot study of continuous, hyperfractionated, accelerated radiation treatment (CHART) there was no significant influence of any of the parameters measured (LI, Ts, Tpo,) on local tumour control. Similar numbers of successes or failures were observed above and below the median value for each parameter (Wilson, 1991) .
Publications examining tumour growth rates and prognosis in other types of malignancy are more common, although studies using in vivo bromodeoxyuridine to assess cell kinetics are yet to appear. In 1989 Tubiana and Courdi reviewed a large number of studies investigating the relationship between survival and the percentage of tumour cells in S-phase assessed by a variety of methods. They concluded that Sphase fraction was of high prognostic significance, particularly in breast cancers, non-Hodgkin's lymphomas, ovarian cancers, neuroblastoma, bladder and lung cancers. It is not clear whether they attempted a comprehensive review of all publications up to 1988 when the manuscript was submitted, but within the head and neck region they omitted the paper by Franzen et al. (1986) . Despite Tubiana and Courdi's strong conclusion on the prognostic usefulness of SPF there have been subsequent large series in both breast and ovarian cancer which found no correlation between SPF and prognosis (Conte et al., 1989; Cooke et al., 1992) .
In conclusion, at present cell kinetic measurements are not sensitive enough to be used clinically to predict prognosis. However, the final results of several prospective studies in different centres are awaited.
